Passage BIO Files 2024 10-K
Ticker: PASG · Form: 10-K · Filed: Mar 4, 2025 · CIK: 1787297
Sentiment: neutral
Topics: 10-K, financials, biotech
TL;DR
Passage BIO dropped its 2024 10-K. Financials for FY24 are in. Check it out.
AI Summary
Passage BIO, Inc. filed its 2024 10-K on March 4, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, focused on biological products, is incorporated in Delaware and headquartered in Philadelphia, PA. Key financial data points such as retained earnings, additional paid-in capital, and accumulated other comprehensive income are reported as of December 31, 2024, and comparative periods.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Passage BIO's financial health and operational status for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a company in the biological products sector, Passage BIO likely faces inherent risks related to research and development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for financial statements)
- 2025-03-04 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Passage BIO, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-04 (date) — Filing date
- Philadelphia, PA (location) — Company headquarters
- 2836 (number) — Standard Industrial Classification for Biological Products
FAQ
What were Passage BIO's total revenues for the fiscal year ended December 31, 2024?
The provided text does not contain specific revenue figures for December 31, 2024. It focuses on filing details and balance sheet components.
What is the company's net income or loss for the fiscal year ended December 31, 2024?
The provided text does not specify the net income or loss for the fiscal year ended December 31, 2024.
What are the details of Passage BIO's 'At the Market Facility Agreement' dated March 5, 2021?
The filing mentions an 'At the Market Facility Agreement' dated March 5, 2021, but the specific terms and details are not included in this excerpt.
How much cash and cash equivalents did Passage BIO have as of December 31, 2024?
The excerpt does not provide information on Passage BIO's cash and cash equivalents as of December 31, 2024.
What are the reported values for Retained Earnings, Additional Paid-In Capital, and Accumulated Other Comprehensive Income as of December 31, 2024?
The filing indicates that Retained Earnings, Additional Paid-In Capital, and Accumulated Other Comprehensive Income are reported as of December 31, 2024, but the specific dollar amounts are not present in this excerpt.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 4, 2025 regarding Passage BIO, Inc. (PASG).